Patents by Inventor Eugenio Castelli

Eugenio Castelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR MAKING SARECYCLINE HYDROCHLORIDE
    Publication number: 20210017123
    Abstract: The described invention relates to sarecycline, related compounds, intermediates and salts thereof and processes for preparing the same.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 21, 2021
    Inventors: Giovanni PALOMBI, Eugenio CASTELLI, Giuseppe MOTTA, Meinrad BRENNER, Ruiliang LU, Shaozhi HUANG, William Paul ARMSTRONG, Gajanan JOSHI, Farzaneh SEYEDI, Sean JOHNSTON
  • Polymorphs of atomoxetine hydrochloride
    Publication number: 20100076225
    Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.
    Type: Application
    Filed: December 3, 2009
    Publication date: March 25, 2010
    Inventors: Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei
  • Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
    Patent number: 7569729
    Abstract: Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any form of Atomoxetine Hydrochloride, and an analytical method for analyzing the stability of Atomoxetine Hydrochloride are provided.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: August 4, 2009
    Assignee: Teva Pharmaceutical Fine Chemicals S.R.L.
    Inventors: Eugenio Castelli, Paolo Riva
  • Process for the preparation of atomoxetine hydrochloride
    Patent number: 7507861
    Abstract: The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: March 24, 2009
    Assignee: Teva Pharmaceutical Fine Chemicals, S.r.l.
    Inventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
  • Polymorphs of atomoxetine hydrochloride
    Patent number: 7473804
    Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: January 6, 2009
    Assignee: Teva Pharmaceutical Fine Chemicals s.r.l.
    Inventors: Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei
  • Polymorphs of atomoxetine hydrochloride
    Publication number: 20080312471
    Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.
    Type: Application
    Filed: August 11, 2008
    Publication date: December 18, 2008
    Inventors: Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei
  • Processes for the preparation of atomoxetine hydrochloride
    Patent number: 7439399
    Abstract: The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water. In preferred embodiments, the atomoxetine hydrochloride produced is Form A.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: October 21, 2008
    Assignee: Teva Pharmaceutical Fine Chemicals
    Inventors: Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei
  • Enantiomerically pure atomoxetine and tomoxetine mandelate
    Patent number: 7439398
    Abstract: The present invention provides enantiomerically pure (R)-(?)-tomoxetine (S)-(+)-mandelate and atomoxetine HCl. The present invention further provides enantiomerically pure (R)-(?)-tomoxetine (S)-(+)-mandelate prepared from racemic tomoxetine. The present invention also provides enantiomerically pure atomoxetine HCl prepared from (R)-(?)-tomoxetine (S)-(+)-mandelate.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: October 21, 2008
    Assignee: Teva Pharmaceutical Fine Chemicals S.R.L.
    Inventors: Eugenio Castelli, Paola Daverio, Silvia Mantovani
  • Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
    Publication number: 20080146675
    Abstract: Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any form of Atomoxetine Hydrochloride, and an analytical method for analyzing the stability of Atomoxetine Hydrochloride are provided.
    Type: Application
    Filed: February 15, 2008
    Publication date: June 19, 2008
    Inventors: Eugenio Castelli, Paolo Riva
  • Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
    Patent number: 7378553
    Abstract: The present invention provides isolated N-methyl-3-(3-methylphenoxy)-3-phenylpropylamine hydrochloride, and preparation thereof as well as of N-methyl-3-(4-methylphenoxy)-3-phenylpropylamine hydrochloride and of N-methyl-3-phenoxy-3-phenylpropylamine hydrochloride. The invention further provides the use of the above compounds as reference markers and/or reference standards during the synthesis of Atomoxetine. Also provided is a method of limiting the amounts of the impurities 3FT (3-fluorotoluene), 4FT (4-fluorotoluene), and FB (fluorobenzene) in the 2-fluorotoluene starting material used in the synthesis of Atomoxetine Hydrochloride. The purity of the Atomoxetine Hydrochloride product is ensured by determining the amounts of 3FT, 4FT, and FB in the 2-fluorotoluene starting material with the marker 3-ATM HCl.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: May 27, 2008
    Assignee: Teva Pharmaceutical Fine Chemicals S.r.l.
    Inventors: Eugenio Castelli, Alessandra Vailati
  • Processes for the preparation of tomoxetine
    Patent number: 7355078
    Abstract: Provided are processes for preparing tomoxetine comprising reacting N-methyl-3-hydroxy-3-phenylpropylamine with dimethylsulfoxide (DMSO) and 2-fluorotoluene in the presence of an alkali base to form tomoxetine. Also provided is the conversion of said tomoxetine into atomoxetine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: April 8, 2008
    Assignee: Teva Pharmaceutical Fine Chemicals S.r.l.
    Inventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
  • Process for the optical resolution and recycling of tomoxetine
    Patent number: 7317127
    Abstract: The present invention provides a process for the optical resolution of racemic tomoxetine under reaction conditions that improve reaction yields and optical purity. The invention also provides an epimerization process for the (S)-(+) enantiomer. The invention further provides the conversion of the enantiomer obtained from the optical resolution into atomoxetine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: January 8, 2008
    Assignee: Teva Pharmaceutical Fine Chemicals S.r.l
    Inventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
  • Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
    Publication number: 20060252836
    Abstract: Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any form of Atomoxetine Hydrochloride, and an analytical method for analyzing the stability of Atomoxetine Hydrochloride are provided.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 9, 2006
    Inventors: Eugenio Castelli, Paolo Riva
  • Processes for the preparation of atomoxetine hydrochloride
    Publication number: 20060211772
    Abstract: The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water. In preferred embodiments, the atomoxetine hydrochloride produced is Form A.
    Type: Application
    Filed: September 7, 2005
    Publication date: September 21, 2006
    Inventors: Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei
  • Polymorphs of atomoxetine hydrochloride
    Publication number: 20060079581
    Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.
    Type: Application
    Filed: July 21, 2005
    Publication date: April 13, 2006
    Inventors: Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei
  • Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
    Publication number: 20060009532
    Abstract: The present invention provides isolated N-methyl-3-(3-methylphenoxy)-3-phenylpropylamine hydrochloride, and preparation thereof as well as of N-methyl-3-(4-methylphenoxy)-3-phenylpropylamine hydrochloride and of N-methyl-3-phenoxy-3-phenylpropylamine hydrochloride. The invention further provides the use of the above compounds as reference markers and/or reference standards during the synthesis of Atomoxetine. Also provided is a method of limiting the amounts of the impurities 3FT (3-fluorotoluene), 4FT (4-fluorotoluene), and FB (fluorobenzene) in the 2-fluorotoluene starting material used in the synthesis of Atomoxetine Hydrochloride. The purity of the Atomoxetine Hydrochloride product is ensured by determining the amounts of 3FT, 4FT, and FB in the 2-fluorotoluene starting material with the marker 3-ATM HCl.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 12, 2006
    Inventors: Eugenio Castelli, Alessandra Vailati
  • Process for the preparation of atomoxetine hydrochloride
    Publication number: 20060009489
    Abstract: The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 12, 2006
    Inventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
  • Processes for the preparation of tomoxetine
    Publication number: 20060009531
    Abstract: Provided are processes for preparing tomoxetine comprising reacting N-methyl-3-hydroxy-3-phenylpropylamine with dimethylsulfoxide (DMSO) and 2-fluorotoluene in the presence of an alkali base to form tomoxetine. Also provided is the conversion of said tomoxetine into atomoxetine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 12, 2006
    Inventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
  • Process for the optical resolution and recycling of tomoxetine
    Publication number: 20060009530
    Abstract: The present invention provides a process for the optical resolution of racemic tomoxetine under reaction conditions that improve reaction yields and optical purity. The invention also provides an epimerization process for the (S)-(+) enantiomer. The invention further provides the conversion of the enantiomer obtained from the optical resolution into atomoxetine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 12, 2006
    Inventors: Eugenio Castelli, Giuseppe Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
  • Enantiomerically pure atomoxetine and tomoxetine mandelate
    Publication number: 20060009490
    Abstract: The present invention provides enantiomerically pure (R)-(?)-tomoxetine (S)-(+)-mandelate and atomoxetine HCl. The present invention further provides enantiomerically pure (R)-(?)-tomoxetine (S)-(+)-mandelate prepared from racemic tomoxetine. The present invention also provides enantiomerically pure atomoxetine HCl prepared from (R)-(?)-tomoxetine (S)-(+)-mandelate.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 12, 2006
    Inventors: Eugenio Castelli, Paola Daverio, Silvia Mantovani